Here are four notes:
1. The CHERISH study is focused on gaining marketing approval of nusinersen in children with spinal muscular atrophy.
2. The study is a randomized, double-blind, sham-procedure lasting 15 months. It involves about 117 children with SMA aged two to 12.
3. Researchers are studying the effect and safety of 12 mg doses of nusinersen, analyzing the change in the Hammersmith Functional Motor Scale-Expanded scale.
4. Ionis Pharmaceutical and Biogen have a partnership that combines Ionis’ antisense technology experience with Biogen’s neurological disorder therapy development expertise.
“We, along with Biogen, are committed to advancing nusinersen toward the market as rapidly as possible,” said B. Lynee Parshall, COO, Ionis Pharmaceuticals.
More articles on spine:
NY spine surgeries migrating to high-volume centers — 5 key points
6 key thoughts on building a spine care registry with EHR data
Cervical Spine Research Society elects Dr. Robert Heary president: 6 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.